Mikyoung Chang
Director, Scientific Affairs/ Scientific Liaison at Bridge Biotherapeutics, Inc. () - , ,
Mikyoung Chang's Colleagues at Bridge Biotherapeutics, Inc. ()
Mikyoung Chang's Contact Details
Houston,Texas,United States
Bridge Biotherapeutics, Inc. ()
Mikyoung Chang's Company Details
Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.